Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylquinoline class of organic compounds. It has the molecular formula C₁₉H₁₃ClN₂O₂ and a molecular weight of approximately 336.77 g/mol[1][2][3]. The compound is experimental and not approved for clinical use in any country[1]. Its primary known biological activity is as an inhibitor of macrophage colony-stimulating factor 1 receptor (CSF1R), with an IC50 value of approximately 140 nM[1]. CSF1R inhibition may have potential applications in modulating immune responses or treating diseases involving macrophage proliferation or function; however, there are no reported clinical trials or approved indications for this molecule as of now[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE.